A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale D, Deyà-Martínez À, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J.
Badolato R, et al. Among authors: bolyard aa.
Blood. 2024 Jul 4;144(1):35-45. doi: 10.1182/blood.2023022658.
Blood. 2024.
PMID: 38643510
Free PMC article.
Clinical Trial.